<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385801</url>
  </required_header>
  <id_info>
    <org_study_id>RIS-EMR-4021</org_study_id>
    <nct_id>NCT00385801</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of the administration of
      Risperidal-Consta on the brain's reward circuitry using Magnetic resonance Imaging (MRI),
      behavioral tests and measuring cocaine craving and use among people with active cocaine
      dependence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional MRI Activation Patterns in the Nucleus Accumbens and Amygdala in Response to Cocaine Cues</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine Use by Quantitative Urine Samples</measure>
    <time_frame>12 weeks</time_frame>
    <description>After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cocaine Craving</measure>
    <time_frame>12 weeks</time_frame>
    <description>The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amygdala Volume by MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo tablets and injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone consta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>risperidone consta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current cocaine dependence who use cocaine at least every 2 weeks

          -  Non-treatment seekers who intend to continue using cocaine

          -  Male 18-60 years of age

          -  Potential participants must be literate in the English language, and be able to
             understand and complete rating scales and questionnaires accurately

          -  Able to provide informed consent

          -  Potential participants must be able to identify at least one &quot;locator&quot; person to
             assist in tracking the participant for follow-up assessments

        Exclusion Criteria:

          -  Other current substance dependence requiring immediate detoxification

          -  Diagnosis of schizophrenia, bipolar disorder, current major depressive disorder

          -  Currently suicidal or at high risk for suicide in the judgment of the investigator

          -  Carrying a medical device incompatible with MRI (e.g., metal implants such as surgical
             clips or pacemakers and extensive dental work such as bridges) or suffering from
             significant claustrophobia that would make MRI unfeasible.

          -  Size incompatible with MRI procedures

          -  Serious medical illness including HIV-1 infection

          -  Hepatitis C + titer with liver enzymes more than 2x normal or a Mini-Mental Status
             Exam Score of &lt;25/30

          -  Insulin dependent diabetes mellitus (IDDM) or non- insulin dependent diabetes mellitus
             (NIDDM) and abnormal Hemoglobin A1C

          -  Severe hepatic or renal impairment

          -  History of seizure disorder, delirium, dementia, or mental disorders due to general
             medical conditions

          -  History of head trauma or stroke with lasting neurological sequelae

          -  Tardive dyskinesia, extrapyramidal movement disorder, Parkinson's Disease or history
             of Neuroleptic Malignant Syndrome

          -  Clinical or laboratory evidence of uncontrolled hypothyroidism/hyperthyroidism

          -  Orthostatic hypotension, defined as a decrease of at &gt; 10 mm Hg in systolic blood
             pressure and/or an increase in heart rate of &gt; 20 beats per minute, measured one
             minute following transition from a supine to a standing position.

          -  History of allergy or hypersensitivity to Risperidone

          -  Treatment with: Neuroleptics, Antidepressants, Antiarrhythmics, Carbamazepine,
             Phenytoin, Valproate, Rifampin, Phenobarbital, Levodopa and other dopamine agonists,
             Fluoxetine, Interferon, Propylthiouracil, Methimazole, Opiates.

          -  Treatment within 30 days prior to screening with an investigational drug or medication
             with the potential to influence cocaine use outcomes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eden A Evins, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH Addiction Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>April 30, 2015</results_first_submitted>
  <results_first_submitted_qc>March 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2017</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>A. Eden Evins</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>dependence</keyword>
  <keyword>risperidal</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from October 2005 to September 2006 via advertisement in local press</recruitment_details>
      <pre_assignment_details>After baseline evaluation participants began treatment with oral risperidone, 1 mg per day the first week and 2 mg per day for the next 3 weeks. Electrocardiograms were repeated after 1 and 2 weeks of risperidone use. Participants with corrected QT interval (QTc) prolongation greater than 470 milliseconds at either of these occasions were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Identical placebo tablets and injections</description>
        </group>
        <group group_id="P2">
          <title>Risperidone Consta</title>
          <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Identical placebo tablets and injections</description>
        </group>
        <group group_id="B2">
          <title>Risperidone Consta</title>
          <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="6.4"/>
                    <measurement group_id="B2" value="44.1" spread="5.9"/>
                    <measurement group_id="B3" value="43" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional MRI Activation Patterns in the Nucleus Accumbens and Amygdala in Response to Cocaine Cues</title>
        <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
        <time_frame>12 weeks</time_frame>
        <population>Measure of Dispersion/Precision not calculated, and raw data are no longer available</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Identical placebo tablets and injections</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Consta</title>
            <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Functional MRI Activation Patterns in the Nucleus Accumbens and Amygdala in Response to Cocaine Cues</title>
          <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
          <population>Measure of Dispersion/Precision not calculated, and raw data are no longer available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use by Quantitative Urine Samples</title>
        <description>After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below</description>
        <time_frame>12 weeks</time_frame>
        <population>Mean number of visits at which participants submitted urine samples with undetectable urine benzoylecgonine (UBE)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Identical placebo tablets and injections</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Consta</title>
            <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use by Quantitative Urine Samples</title>
          <description>After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below</description>
          <population>Mean number of visits at which participants submitted urine samples with undetectable urine benzoylecgonine (UBE)</population>
          <units>visit with negative UBE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="2.29"/>
                    <measurement group_id="O2" value="0.87" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Craving</title>
        <description>The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week)</description>
        <time_frame>12 weeks</time_frame>
        <population>Mixed model repeated measures analysis of variance was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Identical placebo tablets and injections</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving</title>
          <description>The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week)</description>
          <population>Mixed model repeated measures analysis of variance was performed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Raw data to calculate the mean values and measure of Dispersion/Precision are no longer available</measurement>
                    <measurement group_id="O2" value="NA">Raw data to calculate the mean values and measure of Dispersion/Precision are no longer available</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intensity of craving</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>The effect of treatment on intensity of craving was assessed and the threshold for statistical significance was p &lt; 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F=0.03</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amygdala Volume by MRI</title>
        <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
        <time_frame>12 weeks</time_frame>
        <population>Measure of Dispersion/Precision not calculated, and raw data are no longer available</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Identical placebo tablets and injections</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Consta</title>
            <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Amygdala Volume by MRI</title>
          <description>Measure of Dispersion/Precision not calculated, and raw data are no longer available</description>
          <population>Measure of Dispersion/Precision not calculated, and raw data are no longer available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at every visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Identical placebo tablets and injections</description>
        </group>
        <group group_id="E2">
          <title>Risperidone Consta</title>
          <description>Risperidone 1-2 mg tablets and Risperidone 25 mg injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased thirst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity, twitches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Parasthesia, hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tardive dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. Eden Evins, MD, MPH. Director of the MGH-Harvard Center for Addiction Medicine</name_or_title>
      <organization>Massachusetts General Hospital - Harvard Medical School</organization>
      <phone>6176434679</phone>
      <email>a_eden_evins@hms.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

